Status:

COMPLETED

Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Lead Sponsor:

Dong-A ST Co., Ltd.

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

19+ years

Phase:

PHASE3

Brief Summary

This study evaluates the addition of dapagliflozin in the treatment of type 2 diabetes with metformin and evogliptin combination therapy. Half of subjects will receive dapagliflozin, metformin and evo...

Eligibility Criteria

Inclusion

  • Patients with type II diabetes mellitus aged 19 years or older
  • Patients who had taken metformin(≥1000mg/day) and DPP(dipeptidyl peptidase)-4 inhibitor combination therapy(or complex is allowed) at the same dose for at least 8 weeks prior to the screening visit
  • Patients with fasting plasma glucose≤250mg/dL at the screening visit
  • Patients with 18.5kg/m\^2≤BMI≤40kg/m\^2 at the screening visit
  • Patients who have signed an informed consent themselves after receiving detailed explanation about the clinical study

Exclusion

  • Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic coma or -pre-coma, metabolic acidosis including lactic acidosis and diabetic ketoacidosis
  • Patients with a medical history of New York Heart Association(NYHA) class III\~IV heart failure or with congestive heart failure, acute and unstable heart failure
  • Patients with severe infectious disease or severe traumatic systemic disorders
  • Patients with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia
  • Patients with galactose intolerance, lapp lactase deficiency, glucose-galactose malabsorption
  • Patients with moderate to severe stage renal disease, end stage renal disease, dialysis at the time of screening visit

Key Trial Info

Start Date :

May 26 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 23 2022

Estimated Enrollment :

198 Patients enrolled

Trial Details

Trial ID

NCT04356742

Start Date

May 26 2020

End Date

February 23 2022

Last Update

March 22 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Catholic University of Korea Bucheon St. Mary's Hospital

Bucheon-si, South Korea